<DOC>
	<DOCNO>NCT00146718</DOCNO>
	<brief_summary>The project three-armed study design evaluate efficacy amodiaquine ( AQ ) , sulphadoxine-pyrimethamine ( SP ) ( AQ+SP ) three site Cameroon differ baseline characteristic malaria . In addition , drug resistance determine measurement blood drug level , identification molecular marker resistance .</brief_summary>
	<brief_title>Anti-Malarial Drug Resistance Cameroon</brief_title>
	<detailed_description>The objective study : - . - evaluate therapeutic efficacy amodiaquine ( AQ ) , Fansidar ( SP ) combination amodiaquine/Fansidar three site Cameroon namely , Garoua ( Sahel-savanna ) , Yaounde ( Forest-savannah mosaic ) Limbe ( Littoral-forest ) - determine prevalence molecular marker associate resistance chloroquine , AQ , SP Limbe Garoua mefloquine Yaounde . - investigate biological factor may enhance anti-malaria therapeutic efficacy . This involve exploratory , pilot study conduct second year program . Patients rapidly screen temperature send laboratory determine presence absence malaria parasite . The patient examine clinically inclusion exclusion . Consent sort parent child randomise assign study number . To avoid bias assign patient group ensure equal number treatment group , block randomization perform , use table random variable vary block size . The physician blind treatment patient get . Amodiaquine administer 10mg/kg three day child AQ treatment group , together Fansidar dummy tablet . Fansidar give 25 mg/kg day 0 quinine rescue drug 10mg/kg per 8H 6 day . For AQ/SP combination , D0 , patient give 25 mg/kg SP 10mg/kg AQ . On subsequent day AQ dummy tablet ( SP arm ) give . Clinical assessment study include : physical examination monitoring vital sign D0 , D3 , D7 , D14 D28 . Hematological measurement include : blood film , haemoglobin , glucose , blood drug level , baseline haematology . A maximum 3ml blood withdrawn patient Yaoundé complete analysis ( see ) . For patient recruit Limbe Garoua finger prick blood filter paper sample obtain . Day 0 blood sample ( 3mL ) collect aseptically venepuncture therapy 50 patient Yaoundé use acid-citrate-dextrose buffer ( ACD ) anticoagulant . This process provide plasma immunological determination haematology blood drug level determination . The molecular characterization diversity mutation : - genetic heterogeneity study population establish use primer msp1 msp2 show previously distinguish strain . - PCR product digest restriction enzyme ( RFLP-PCR ) pyrimethamine resistance gene dhfr dhps , chloroquine resistant strain pfcrtgene .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Inclusion criterion : Children 659 month age Recorded temperature 37.5oC 39.5 oC Signs/symptoms acute uncomplicated P. falciparum malaria . Positive microscopy monoinfection P falciparum malaria Asexual blood stage parasitaemia range 1,000 100,000 asexual parasite per ul Consent parent guardian child . No apparent cause child 's illness . Exclusion criterion : Presence sign severe complicate falciparum malaria . Cerebral malaria ( unrousable coma ) Vomiting &gt; twice within precede 24 hour More one convulsion within precede 24 hour Inability drink breastfeed , take oral medication Haemoglobin le 5g/dl hematocrit less 15 % . Documented evidence adequate treatment drug expect effective precede 72 hour Presence underlie disease ( cardiac , renal , hepatic , malnutrition , gastrointestinal ) History allergy study drug Inability attend stipulate followup visit , Difficulty access health facility , situation condition may compromise patient ability comply trial procedure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>malaria</keyword>
	<keyword>drug resistance</keyword>
	<keyword>antimalarial</keyword>
</DOC>